S&P 500   4,262.54 (-0.59%)
DOW   33,294.61 (-0.64%)
QQQ   358.92 (+0.18%)
AAPL   172.93 (+1.00%)
MSFT   318.85 (+0.98%)
META   303.89 (+1.23%)
GOOGL   133.02 (+1.65%)
AMZN   128.75 (+1.28%)
TSLA   249.12 (-0.44%)
NVDA   444.27 (+2.13%)
NIO   8.73 (-3.43%)
BABA   86.14 (-0.69%)
AMD   101.91 (-0.89%)
T   14.71 (-2.06%)
F   12.27 (-1.21%)
MU   67.25 (-1.15%)
CGC   0.73 (-6.16%)
GE   108.61 (-1.75%)
DIS   81.31 (+0.32%)
AMC   8.09 (+1.25%)
PFE   33.71 (+1.63%)
PYPL   58.51 (+0.09%)
NFLX   379.28 (+0.44%)
S&P 500   4,262.54 (-0.59%)
DOW   33,294.61 (-0.64%)
QQQ   358.92 (+0.18%)
AAPL   172.93 (+1.00%)
MSFT   318.85 (+0.98%)
META   303.89 (+1.23%)
GOOGL   133.02 (+1.65%)
AMZN   128.75 (+1.28%)
TSLA   249.12 (-0.44%)
NVDA   444.27 (+2.13%)
NIO   8.73 (-3.43%)
BABA   86.14 (-0.69%)
AMD   101.91 (-0.89%)
T   14.71 (-2.06%)
F   12.27 (-1.21%)
MU   67.25 (-1.15%)
CGC   0.73 (-6.16%)
GE   108.61 (-1.75%)
DIS   81.31 (+0.32%)
AMC   8.09 (+1.25%)
PFE   33.71 (+1.63%)
PYPL   58.51 (+0.09%)
NFLX   379.28 (+0.44%)
S&P 500   4,262.54 (-0.59%)
DOW   33,294.61 (-0.64%)
QQQ   358.92 (+0.18%)
AAPL   172.93 (+1.00%)
MSFT   318.85 (+0.98%)
META   303.89 (+1.23%)
GOOGL   133.02 (+1.65%)
AMZN   128.75 (+1.28%)
TSLA   249.12 (-0.44%)
NVDA   444.27 (+2.13%)
NIO   8.73 (-3.43%)
BABA   86.14 (-0.69%)
AMD   101.91 (-0.89%)
T   14.71 (-2.06%)
F   12.27 (-1.21%)
MU   67.25 (-1.15%)
CGC   0.73 (-6.16%)
GE   108.61 (-1.75%)
DIS   81.31 (+0.32%)
AMC   8.09 (+1.25%)
PFE   33.71 (+1.63%)
PYPL   58.51 (+0.09%)
NFLX   379.28 (+0.44%)
S&P 500   4,262.54 (-0.59%)
DOW   33,294.61 (-0.64%)
QQQ   358.92 (+0.18%)
AAPL   172.93 (+1.00%)
MSFT   318.85 (+0.98%)
META   303.89 (+1.23%)
GOOGL   133.02 (+1.65%)
AMZN   128.75 (+1.28%)
TSLA   249.12 (-0.44%)
NVDA   444.27 (+2.13%)
NIO   8.73 (-3.43%)
BABA   86.14 (-0.69%)
AMD   101.91 (-0.89%)
T   14.71 (-2.06%)
F   12.27 (-1.21%)
MU   67.25 (-1.15%)
CGC   0.73 (-6.16%)
GE   108.61 (-1.75%)
DIS   81.31 (+0.32%)
AMC   8.09 (+1.25%)
PFE   33.71 (+1.63%)
PYPL   58.51 (+0.09%)
NFLX   379.28 (+0.44%)
NASDAQ:LTRN

Lantern Pharma (LTRN) Stock Forecast, Price & News

$3.28
-0.13 (-3.81%)
(As of 02:34 PM ET)
Compare
Today's Range
$3.25
$3.43
50-Day Range
$3.41
$5.00
52-Week Range
$3.25
$6.20
Volume
14,973 shs
Average Volume
34,365 shs
Market Capitalization
$35.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00

Lantern Pharma MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
236.4% Upside
$11.00 Price Target
Short Interest
Healthy
2.09% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.93mentions of Lantern Pharma in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.75) to ($2.27) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.86 out of 5 stars

Medical Sector

752nd out of 969 stocks

Pharmaceutical Preparations Industry

363rd out of 453 stocks


LTRN stock logo

About Lantern Pharma (NASDAQ:LTRN) Stock

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. It develops LP-100 for treatment in combination with the class of anticancer agent known as PARP inhibitors. The company also develops LP-300 as a combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; and LP-284, a novel small molecule and DNA damaging agent for the treatment of mantle cell lymphoma and double hit lymphoma. In addition, it offers LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

LTRN Price History

LTRN Stock News Headlines

8 Best Artificial Intelligence Stocks Under $10 (LTRN)
If you want to get in on artificial intelligence (AI) but don’t want to spend a lot, why not consider artificial intelligence stocks under $10? Learn more.
LTRN: Spotlight on LP-184 & 284
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
LTRN: 2Q:23 Quarterly Update
Lantern Pharma (LTRN) Receives a Hold from H.C. Wainwright
LTRN - Lantern Pharma Inc.
LTRN: First Harmonic Patient Dosed
See More Headlines
Receive LTRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lantern Pharma and its competitors with MarketBeat's FREE daily newsletter.

LTRN Company Calendar

Last Earnings
8/09/2023
Today
10/02/2023
Next Earnings (Estimated)
11/06/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LTRN
Fax
N/A
Employees
22
Year Founded
2013

Price Target and Rating

Average Stock Price Forecast
$11.00
High Stock Price Forecast
$11.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+222.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-14,260,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.16 per share

Miscellaneous

Free Float
10,117,000
Market Cap
$37.07 million
Optionable
Not Optionable
Beta
0.75

Social Links

7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Panna Sharma PH.D. (Age 52)
    Pres, CEO & Director
    Comp: $633.25k
  • Mr. David R. Margrave (Age 62)
    CFO & Sec.
    Comp: $394.36k
  • Dr. Kishor Gopaldas Bhatia Ph.D. (Age 68)
    Chief Scientific Officer & Scientific Consultant
    Comp: $184.33k
  • Nicole Leber
    Investor Relations Associate, Fin. & Admin. Coordinator
  • Dr. Peter L. Nara D.V.M.
    M.S., Ph.D., Co-Founder & Advisor
  • Mr. Ernest Kitt B.S.
    M.S, Head of Clinical Operations













LTRN Stock - Frequently Asked Questions

Should I buy or sell Lantern Pharma stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lantern Pharma in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" LTRN shares.
View LTRN analyst ratings
or view top-rated stocks.

What is Lantern Pharma's stock price forecast for 2023?

2 brokers have issued 1-year price targets for Lantern Pharma's stock. Their LTRN share price forecasts range from $11.00 to $11.00. On average, they expect the company's stock price to reach $11.00 in the next year. This suggests a possible upside of 222.6% from the stock's current price.
View analysts price targets for LTRN
or view top-rated stocks among Wall Street analysts.

How have LTRN shares performed in 2023?

Lantern Pharma's stock was trading at $6.04 at the start of the year. Since then, LTRN stock has decreased by 43.5% and is now trading at $3.41.
View the best growth stocks for 2023 here
.

When is Lantern Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our LTRN earnings forecast
.

How were Lantern Pharma's earnings last quarter?

Lantern Pharma Inc. (NASDAQ:LTRN) issued its quarterly earnings data on Wednesday, August, 9th. The company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.40) by $0.04.

What ETFs hold Lantern Pharma's stock?

ETFs with the largest weight of Lantern Pharma (NASDAQ:LTRN) stock in their portfolio include Horizon Kinetics Medical ETF (MEDX),

What other stocks do shareholders of Lantern Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lantern Pharma investors own include Applied Materials (AMAT), ARK Next Generation Internation ETF (ARKW), Conagra Brands (CAG), FedEx (FDX), Lowe's Companies (LOW), PayPal (PYPL), Block (SQ), Vanguard Real Estate ETF (VNQ) and ARK Innovation ETF (ARKK).

When did Lantern Pharma IPO?

(LTRN) raised $26 million in an IPO on Thursday, June 11th 2020. The company issued 1,600,000 shares at a price of $15.00-$17.00 per share. ThinkEquity (a division of Fordham Financial Management) acted as the underwriter for the IPO and Dougherty & Company and Paulson Investment Company were co-managers.

What is Lantern Pharma's stock symbol?

Lantern Pharma trades on the NASDAQ under the ticker symbol "LTRN."

How do I buy shares of Lantern Pharma?

Shares of LTRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lantern Pharma's stock price today?

One share of LTRN stock can currently be purchased for approximately $3.41.

How much money does Lantern Pharma make?

Lantern Pharma (NASDAQ:LTRN) has a market capitalization of $37.07 million. The company earns $-14,260,000.00 in net income (profit) each year or ($1.32) on an earnings per share basis.

How can I contact Lantern Pharma?

Lantern Pharma's mailing address is 1920 MCKINNEY AVENUE 7TH FLOOR, DALLAS TX, 75201. The official website for the company is www.lanternpharma.com. The company can be reached via phone at 972-277-1136 or via email at info@lanternpharma.com.

This page (NASDAQ:LTRN) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -